Savient Secures Last-Minute Generic Oxandrin Ban

Law360, New York (December 13, 2006, 12:00 AM EST) -- Drug maker Savient Pharmaceuticals Inc. was able to buy more time for its weight-gain treatment Oxandrin Tuesday when it persuaded a U.S. federal appeals court at the last minute to issue a temporary restraining order blocking all sales of generic versions of the drug.

Savient said Tuesday’s ruling followed its appeal of last week’s order by the U.S. District Court for the District of New Jersey, which was set to lift a separate temporary generic ban late on Tuesday.

The U.S. Court of Appeals for the...
To view the full article, register now.